Immuneering
IMRX
52 hedge funds and large institutions have $119M invested in Immuneering in 2023 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 17 increasing their positions, 18 reducing their positions, and 4 closing their positions.
0% more funds holding
Funds holding: 52 → 52 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
6% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 18
2.6% less ownership
Funds ownership: 57.9% → 55.3% (-2.6%)
9% less capital invested
Capital invested by funds: $130M → $119M (-$11.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$606K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$200K |
| 3 |
Barclays
London,
United Kingdom
|
+$178K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$83.9K |
| 5 |
State Street
Boston,
Massachusetts
|
+$82.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.76M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.03M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$818K |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$633K |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$629K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MLICM
51
Metropolitan Life Insurance Company (MetLife)
New York
| $8.58K | – | – | – |
|
|
HI
52
Harbour Investments
Madison,
Wisconsin
| $184 | – | – | – |
|
53
Invesco
Atlanta,
Georgia
| – | -$78.7K | -10,249 | Closed |
|
|
CUAMC
54
China Universal Asset Management Company
Shanghai,
China
| – | -$5.75K | -749 | Closed |
|
55
Daiwa Securities Group
Tokyo,
Japan
| – | -$1K | -76 | Closed |
|
56
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$576 | -75 | Closed |
|
IMRX Hedge Fund Activity: Q4 2023 in Review
52 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Immuneering (IMRX) for Q4 2023, worth a combined $119M — down 8.6% from $130M a quarter earlier.
Fund positioning in IMRX was balanced in Q4 2023: 4 funds opened new positions, 4 closed out, 17 added to existing stakes and 18 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $606K. The largest seller was BlackRock, cutting an estimated $2.76M.
- 52 institutional investors held Immuneering (IMRX) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $119M of Immuneering stock for Q4 2023, down 8.6% quarter-over-quarter.
- 4 funds opened new Immuneering positions in Q4 2023 and 4 closed out, a net change of 0 holders.
- The largest Immuneering buyer in Q4 2023 was Morgan Stanley, an estimated $606K added.
- The largest Immuneering seller in Q4 2023 was BlackRock, an estimated $2.76M sold.
Based on aggregated 13F filings for Q4 2023.